AU2251488A - Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system - Google Patents

Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system

Info

Publication number
AU2251488A
AU2251488A AU22514/88A AU2251488A AU2251488A AU 2251488 A AU2251488 A AU 2251488A AU 22514/88 A AU22514/88 A AU 22514/88A AU 2251488 A AU2251488 A AU 2251488A AU 2251488 A AU2251488 A AU 2251488A
Authority
AU
Australia
Prior art keywords
acnpv
baculovirus
csf
production
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22514/88A
Inventor
Robin Clark
James Joseph Devlin
Ernest Seigo Kawasaki
George Martin
Edward O'rourke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of AU2251488A publication Critical patent/AU2251488A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU22514/88A 1987-07-24 1988-07-20 Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system Abandoned AU2251488A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7718887A 1987-07-24 1987-07-24
US077188 1987-07-24

Publications (1)

Publication Number Publication Date
AU2251488A true AU2251488A (en) 1989-03-01

Family

ID=22136589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22514/88A Abandoned AU2251488A (en) 1987-07-24 1988-07-20 Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system

Country Status (3)

Country Link
AU (1) AU2251488A (en)
CA (1) CA1317244C (en)
WO (1) WO1989001038A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04228066A (en) * 1990-10-23 1992-08-18 Rikagaku Kenkyusho Culture cell for expressing exogenote
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
JP2003535065A (en) 2000-05-31 2003-11-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Preparation of adjuvant for induction of specific immunity
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101699142B1 (en) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 Novel antigen-binding polypeptides and their uses
CN103520735B (en) 2004-12-22 2015-11-25 Ambrx公司 Comprise non-naturally encoded amino acid whose formulations of human growth hormone
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2007007591A (en) 2004-12-22 2007-07-25 Ambrx Inc Methods for expression and purification of recombinant human growth hormone.
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
JP2008541769A (en) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
PT2339014E (en) 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
KR20090060294A (en) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 Modified human plasma polypeptide or fc scaffolds and their uses
ES2465473T3 (en) 2006-09-08 2014-06-05 Ambrx, Inc. Transcription of arnt suppressor in vertebrate cells
CN104163864B (en) 2007-03-30 2017-08-01 Ambrx公司 Through modifying the polypeptides of FGF 21 and its purposes
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5547083B2 (en) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド Modified insulin polypeptides and their use
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
UA118536C2 (en) 2008-07-23 2019-02-11 Амбркс, Інк. MODIFIED Bovine granulocyte colony-stimulating factor polypeptide and its application
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
KR101647164B1 (en) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 Modified animal erythropoietin polypeptides and their uses
CN107056929A (en) 2009-12-21 2017-08-18 Ambrx 公司 Porcine somatotropin polypeptide and its purposes by modification
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
PL3412302T3 (en) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN110637027B (en) 2017-02-08 2024-08-30 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
IE60819B1 (en) * 1984-07-06 1994-08-10 Sandoz Ltd Lymphokine production and purification
HU215241B (en) * 1986-10-24 1998-11-30 Cetus Corp. Process for producing new forms of colony stimulating factor-1 and expression cassette, vector and recombinant host cells used in the process

Also Published As

Publication number Publication date
CA1317244C (en) 1993-05-04
WO1989001038A1 (en) 1989-02-09

Similar Documents

Publication Publication Date Title
AU2251488A (en) Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
AU648982B2 (en) Capsule production using biologically active substrates
AU6906087A (en) Perimeter resin feeding of composite structures
AU7469787A (en) Process for the genetic modification of yeast
AU3167389A (en) Production of 2',3'-dideoxy-2',3'-didehydronucleosides
AU588981B2 (en) Improvements relating to the production of beer
DE3660768D1 (en) Process for producing physiologically active substance
AU589075B2 (en) System of modular construction for a covered structure
AU5300386A (en) Pharmaceutically active podophyllotoxins
AU582956B2 (en) Production of ceramic materials
HUT50758A (en) Process for production of optically active naftotiasepinons
AU596678B2 (en) Production of crystalline tribromostyrene
AU1050488A (en) Active control of vibration
AU1969688A (en) Manufacture of solar cells
AU3735389A (en) Production of alcohols
AU558388B2 (en) Production of n-acylphenylalanines
AU1572588A (en) Production of bioadhesive precursor protein analogs by genetically-engineered organisms
AU4298289A (en) Method for the preparation of a biologically active substance
AU6581186A (en) Pharmaceutically active hererocyclic compounds
AU4742990A (en) Production of sugar compounds
DE3663257D1 (en) Antihelmintic avermectin derivatives produced by the fermentation of a microorganism
AU573085B2 (en) Production of monotertiarybutyl toluinediamines
EP0207636A3 (en) Process for producing optically active dichloropropanol using microorganism
AU592862B2 (en) Yeast production of streptolinase
JPS6487770A (en) Production of molybdenum membrane